New combo therapy targets Hard-to-Treat stomach cancer
NCT ID NCT04522336
First seen Nov 01, 2025 · Last updated Jun 20, 2026 · Updated 32 times
Summary
This early-phase trial is testing whether adding the immunotherapy drug pembrolizumab to standard chemoradiotherapy can help control gastroesophageal cancer that cannot be removed by surgery. The study includes 16 participants and primarily looks at safety and whether the cancer disappears after treatment. It is a small, early study, so results are preliminary.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CLINICAL STAGE III GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA AJCC V8 are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
pembrolizumab (immunotherapy) plus chemotherapy (docetaxel, fluorouracil, oxaliplatin) and radiation therapy
What this could lead to
If successful, this combination could offer a new treatment option for people with gastroesophageal cancer that cannot be surgically removed.
What could go wrong
This is a very early phase 1 trial with only 16 participants, so results may not apply broadly. Side effects from the drug combination and radiation could be significant.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.